DaVita
About: DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Employees: 70,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
90% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 49
14% more capital invested
Capital invested by funds: $10.8B [Q2] → $12.2B (+$1.48B) [Q3]
7% more funds holding
Funds holding: 550 [Q2] → 589 (+39) [Q3]
3.3% less ownership
Funds ownership: 88.69% [Q2] → 85.38% (-3.3%) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 218
20% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]
22% less call options, than puts
Call options by funds: $243M | Put options by funds: $313M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Barclays Andrew Mok 30% 1-year accuracy 19 / 63 met price target | 1%downside $164 | Equal-Weight Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 11 articles about DVA published over the past 30 days
